HOME >> BIOLOGY >> NEWS
Cancer cells lose drug resistance following electrical stimulation in vitro

Drug-resistant tumour cells lose their drug resistance when exposed to low intensity, low frequency electric pulses for three days. A study published today in the open access journal BMC Cancer reveals that treating drug-resistant tumour cells with electric pulses in vitro restores the cells' ability to take up the anti-cancer drug doxorubicin.

The research group led by Luca Cucullo and Damir Janigro from the Cleveland Clinic Lerner College of Medicine, Ohio, USA exposed rat and human tumour cells to very low intensity (7.5 microamps) 50 Hertz alternating current pulses, with a ten-second interval, for three days in vitro. Such electrical stimulation is known not to damage cells but to decrease the proliferation of tumour cells. The tumour cell lines used overexpress the MDR1 protein, which makes them resistant to anti-cancer drugs such as doxorubicin. Following the three days of electrical stimulation, the cells were exposed to increasing concentrations of doxorubicin for three hours.

Janigro et al.'s results show that electrical stimulation led to an increased uptake of doxorubicin, which caused the cells to die, even at low doxorubicin concentrations. Exposing the cells to an electric current was more effective than treating the cells with an MDR1 inhibitor. These findings suggest the potential application of electrical stimulation to improve the efficacy of existing chemotherapeutic treatments.


'"/>

Contact: Juliette Savin
press@biomedcentral.com
44-207-631-9931
BioMed Central
16-Mar-2006


Page: 1

Related biology news :

1. Journalists can register now for ECCO 14 -- the European Cancer Conference
2. Cancer cures could work for canines and humans
3. The Cancer Genome Atlas awards funds for technology development
4. Cancer research specialist and HSPH professor awarded Medal of Honor from WHO cancer agency
5. Cancer stem cells similar to normal stem cells can thwart anti-cancer agents
6. Cancer stem cells can go it alone
7. Cancer drug enhances long-term memory
8. Cancer cells reprogram energy needs to grow and spread, study suggests
9. Cancer scientists create human leukemia process to map how disease begins, progresses
10. Cancer tip -- Nanoparticles can damage DNA, increase cancer risk
11. Other highlights from the April 18 Journal of the National Cancer Institute

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/26/2020)... ... August 25, 2020 , ... ... in partnership with Essex Bio-Technology, a bio-pharmaceutical company specializing in Ophthalmology and ... study of SkQ1 ophthalmic solution in patients with moderate to severe Dry ...
(Date:8/26/2020)... ... ... Modality Solutions, a biopharmaceutical cold chain validation engineering firm, is ... is the most prestigious ranking of the nation’s fastest-growing private companies. Modality Solutions made ... three-year revenue growth of 71 percent. , The Inc. 5000 list represents a ...
(Date:8/21/2020)... ... August 18, 2020 , ... Sentien Biotechnologies, ... that the U.S. Food and Drug Administration (FDA) has approved the company’s Investigational ... the treatment of severe COVID-19. Approval of this IND allows Sentien to initiate ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... BEDFORD, Mass. (PRWEB) , ... July 29, 2020 ... ... of highly reliable, solid-state radar transmitter systems that can be configured to drive ... a single controller that can drive one or two switches in a push-pull ...
(Date:7/31/2020)... (PRWEB) , ... July 29, 2020 , ... ... 200 of the top radiation centers in 16 countries, has reached its 20th ... SDX® is now in routine use at top universities including University of Pennsylvania, ...
(Date:7/18/2020)... ... July 16, 2020 , ... “We are thrilled to deliver this new technology ... technology of its kind on the market and we were pleased that the IFT ... of traditional cultured ingredients, creating a natural way to extend the shelf life and ...
(Date:7/10/2020)... ... July 09, 2020 , ... ... Technology (MIT) has expanded the company’s exclusive license to include clinical applications ... point-of-care diagnostic market, focusing initially on the SARS-CoV-2 biosensor. CANARY’s™ fast ...
Breaking Biology Technology:
Cached News: